Abstract:COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients show evidence of central nervous system (CNS) damage, predominantly ischaemic, in some cases haemorrhagic and occasionally encephalitic. It is unclear how much of the ischaemic damage is mediated by direct or inflammatory effects of virus on the CNS vasculature and how much is secondary to extracranial cardiorespiratory disease. Limited data suggest that the causative SARS-CoV-2 virus may enter the CNS via the nasal mucosa and olfactory fibres, or by haematogenous spread, and is capable of infecting endothelial cells, pericytes and probably neurons. Extracranially, SARS-CoV-2 targets endothelial cells and pericytes, causing endothelial cell dysfunction, vascular leakage and immune activation, sometimes leading to disseminated intravascular coagulation. It remains to be confirmed whether endothelial cells and pericytes in the cerebral vasculature are similarly targeted. Several aspects of COVID-19 are likely to impact on cognition. Cerebral white matter is particularly vulnerable to ischaemic damage in COVID-19 and is also critically important for cognitive function. There is accumulating evidence that cerebral hypoperfusion accelerates amyloid-β (Aβ) accumulation and is linked to tau and TDP-43 pathology, and by inducing phosphorylation of α-synuclein at serine-129, ischaemia may also increase the risk of development of Lewy body disease. Current therapies for COVID-19 are understandably focused on supporting respiratory function, preventing thrombosis and reducing immune activation. Since angiotensin-converting enzyme (ACE)-2 is a receptor for SARS-CoV-2, and ACE inhibitors and angiotensin receptor blockers are predicted to increase ACE-2 expression, it was initially feared that their use might exacerbate COVID-19. Recent meta-analyses have instead suggested that these medications are protective. This is perhaps because SARS-CoV-2 entry may deplete ACE-2, tipping the balance towards angiotensin II-ACE-1-mediated classical RAS activation: exacerbating hypoperfusion and promoting inflammation. It may be relevant that APOE ε4 individuals, who seem to be at increased risk of COVID-19, also have lowest ACE-2 activity. COVID-19 is likely to leave an unexpected legacy of long-term neurological complications in a significant number of survivors. Cognitive follow-up of COVID-19 patients will be important, especially in patients who develop cerebrovascular and neurological complications during the acute illness.

COVID-19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction

SARS-COV-2 induces blood-brain barrier and choroid plexus barrier impairments and vascular inflammation in mice

SARS‐CoV‐2 induces blood‐brain barrier and choroid plexus barrier impairments and vascular inflammation in mice

Brain Pathology in COVID-19: Clinical Manifestations and Potential Mechanisms

COVID-19: Neuroinvasiveness, Neurotropism and Neurovirulence

Role of the SARS-CoV-2 Virus in Brain Cells

Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms

Neurological Manifestations of Patients with COVID-19: Potential Routes of SARS-CoV-2 Neuroinvasion from the Periphery to the Brain

Cognitive impact of COVID-19: looking beyond the short term

The neurobiology of SARS-CoV-2 infection

Nervous system involvement after infection with COVID-19 and other coronaviruses

Neurological Complications of COVID-19 and Possible Neuroinvasion Pathways: A Systematic Review

Neurological Involvement in COVID-19 and Potential Mechanisms: A Review

Impact Of Sars-Cov-2 Infection On Cognitive Function: A Systematic Review

Neurological complications and infection mechanism of SARS-CoV-2

Vascular Dysfunctions Contribute to the Long-Term Cognitive Deficits Following COVID-19

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment

Neurological Complications Associated with the Blood-Brain Barrier Damage Induced by the Inflammatory Response During SARS-CoV-2 Infection

Neurovascular coupling impairment as a mechanism for cognitive deficits in COVID-19

COVID-19 and the brain: understanding the pathogenesis and consequences of neurological damage

Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience